Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 4/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 3/20 | 0.41 |
| ▸ | MAOB | P27338 | 3/20 | 0.41 |
| ▸ | HTR6 | P50406 | 2/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | PRCP | P42785 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10866922 | 0.82 | HTR2A (0.52) | PDPK1HTR1ASLC18A3MAOAMAOB | |
| SCHEMBL464668 | 0.81 | SIGMAR1 (0.39) | — | |
| SCHEMBL22768719 | 0.81 | SIGMAR1 (0.39) | — | |
| SCHEMBL13616986 | 0.81 | SIGMAR1 (0.39) | — | |
| SCHEMBL16770602 | 0.81 | SIGMAR1 (0.39) | — | |
| SCHEMBL16770603 | 0.81 | SIGMAR1 (0.39) | — | |
| SCHEMBL3830048 | 0.79 | MTNR1A (0.43) | PDPK1HTR1ADRD2MAOAMAOB | |
| SCHEMBL3601105 | 0.79 | IDO1 (0.44) | PDPK1HTR1ADRD2MAOAMAOB | |
| SCHEMBL9115029 | 0.77 | HTR6 (0.54) | PDPK1HTR1ADRD2MAOAMAOB | |
| SCHEMBL19419825 | 0.76 | DRD2 (0.50) | PDPK1DRD2SLC18A3IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192671-A1 | COMPOUNDS FOR THE TREATMENT OF SARS | PURDUE RESEARCH FOUNDATION | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192671-A1 | COMPOUNDS FOR THE TREATMENT OF SARS | ACE2, ACE, SARS1 | PDPK1 2064/4885HTR1A 3165/4885DRD2 4117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.